Eric Donnenfeld, MD
Ophthalmology · Garden City, NYNPI 1891790770
Payments from drug & device makers
Across 1,026 payments — averaging $2560.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$882K
- Shire North American Group Inc$265K
- Alcon$238K
- Bausch & Lomb Americas Inc.$180K
- Ocular Therapeutix, Inc.$159K
- Omeros Corporation$154K
- plus $749K from 39 others
Across 8 payments — averaging $20,833 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Surgical Vision, Inc.$143K
- Rayner Intraocular Lenses Limited$23K
What the payments were for
- Consulting fees$998,86770%
- Speaking & faculty fees$182,23313%
- Grants$12,0491%
- Travel & lodging$13,0281%
- Food & beverage$32,0222%
- Education$4,6160%
- Gifts$10,1241%
- Other$169,53912%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$170,645
- OMIDRIA$105,990
- Compact Intuitiv$97,801
- INTRALASE FS FEMTOSEC LASER$97,801
- IFS ADVANCED FEMTOSEC LASER$96,713
- XIIDRA$85,227
- MIEBO$56,264
- iStent inject Trabecular Micro-Bypass Stent System$50,286
- iStent Trabecular Micro-Bypass Stent System$50,162
- CATALYS SYSTEM$49,323
- Tecnis 1-piece IOL$40,628
- Tecnis 3-piece IOL$38,969
- Tecnis Symphony IOL$38,969
- Tecnis Symphony Toric IOL$38,969
- ILUX$37,915
- Catalys Laser System$25,382
- COMPACT INTUITIV Phacofragmentation System$24,513
- Lacrifill$24,257
- iStent inject W$20,757
- iStent$20,465
How this compares
$2,626,624 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 44 | $77,987 |
| RestasisCyclosporine | 60 | $72,493 |
| Bromfenac Sodium | 722 | $65,991 |
| MieboPerfluorohexyloctane/Pf | 30 | $44,800 |
| XiidraLifitegrast | 38 | $40,188 |
| Prednisolone Acetate | 1,159 | $36,903 |
| ProlensaBromfenac Sodium | 110 | $36,902 |
| Ofloxacin | 1,120 | $13,445 |
| Cyclosporine | 17 | $11,144 |
| Loteprednol Etabonate | 70 | $10,314 |
| EysuvisLoteprednol Etabonate | 19 | $9,295 |
| LumiganBimatoprost | 13 | $7,367 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 68 | $3,063 |
| Difluprednate | 22 | $2,979 |
| MoxifloxacinMoxifloxacin Hcl | 119 | $2,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $179,510 | $84,98868 claims |
| AbbVieRestasis, Lumigan | $16,284 | $79,86073 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $146,652 | $77,98744 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $4,756 | $47,216180 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $13,973 | $9,29519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Garden City
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
- Jonathan JonischGreat Neck$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.